180 related articles for article (PubMed ID: 32674213)
1. Interim Phase 2 ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL.
Slater H
Oncology (Williston Park); 2020 Jul; 34(7):260. PubMed ID: 32674213
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
[TBL] [Abstract][Full Text] [Related]
3. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS; Chavez JC; Sehgal AR; Epperla N; Ulrickson M; Bachy E; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Oluwole OO; Yakoub-Agha I; Khanal R; Rosenblatt J; Korn R; Peng W; Lui C; Wulff J; Shen R; Poddar S; Jung AS; Miao H; Beygi S; Jacobson CA
Blood; 2024 Feb; 143(6):496-506. PubMed ID: 37879047
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
[TBL] [Abstract][Full Text] [Related]
5. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA; Chavez JC; Sehgal AR; William BM; Munoz J; Salles G; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Yakoub-Agha I; Oluwole OO; Fung HCH; Rosenblatt J; Rossi JM; Goyal L; Plaks V; Yang Y; Vezan R; Avanzi MP; Neelapu SS
Lancet Oncol; 2022 Jan; 23(1):91-103. PubMed ID: 34895487
[TBL] [Abstract][Full Text] [Related]
6. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Nastoupil LJ; Jain MD; Feng L; Spiegel JY; Ghobadi A; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Sehgal AR; Goy A; Hill BT; Vu K; Andreadis C; Munoz J; Westin J; Chavez JC; Cashen A; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Locke FL
J Clin Oncol; 2020 Sep; 38(27):3119-3128. PubMed ID: 32401634
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
Ghione P; Palomba ML; Ray MD; Limbrick-Oldfield EH; Owen J; Kanters S; Bobillo S; Ribiero MT; Jacobson CA; Neelapu SS; Ghesquieres H; Nahas M; Beygi S; Patel AR; Gribben JG
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e191-e195.e6. PubMed ID: 38365528
[TBL] [Abstract][Full Text] [Related]
8. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.
Jacobson CA; Locke FL; Ma L; Asubonteng J; Hu ZH; Siddiqi T; Ahmed S; Ghobadi A; Miklos DB; Lin Y; Perales MA; Lunning MA; Herr MM; Hill BT; Ganguly S; Dong H; Nikiforow S; Hooper M; Kawashima J; Xu H; Pasquini MC
Transplant Cell Ther; 2022 Sep; 28(9):581.e1-581.e8. PubMed ID: 35609867
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Ghione P; Palomba ML; Patel AR; Bobillo S; Deighton K; Jacobson CA; Nahas M; Hatswell AJ; Jung AS; Kanters S; Snider JT; Neelapu SS; Ribeiro MT; Brookhart MA; Ghesquieres H; Radford J; Gribben JG
Blood; 2022 Aug; 140(8):851-860. PubMed ID: 35679476
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.
Bouchkouj N; Kasamon YL; de Claro RA; George B; Lin X; Lee S; Blumenthal GM; Bryan W; McKee AE; Pazdur R
Clin Cancer Res; 2019 Mar; 25(6):1702-1708. PubMed ID: 30413526
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
[TBL] [Abstract][Full Text] [Related]
12. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
13. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
Jacobson CA; Hunter BD; Redd R; Rodig SJ; Chen PH; Wright K; Lipschitz M; Ritz J; Kamihara Y; Armand P; Nikiforow S; Rogalski M; Maakaron J; Jaglowski S; Maus MV; Chen YB; Abramson JS; Kline J; Budde E; Herrera A; Mei M; Cohen JB; Smith SD; Maloney DG; Gopal AK; Frigault MJ; Acharya UH
J Clin Oncol; 2020 Sep; 38(27):3095-3106. PubMed ID: 32667831
[TBL] [Abstract][Full Text] [Related]
14. Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.
Cohen JA; Ghobadi A
Expert Rev Anticancer Ther; 2022 Sep; 22(9):903-914. PubMed ID: 35786133
[TBL] [Abstract][Full Text] [Related]
15. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336
[TBL] [Abstract][Full Text] [Related]
16. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.
Ying Z; Yang H; Guo Y; Li W; Zou D; Zhou D; Wang Z; Zhang M; Wu J; Liu H; Zhang P; Yang S; Zhou Z; Zheng H; Song Y; Zhu J
Cancer Med; 2021 Feb; 10(3):999-1011. PubMed ID: 33382529
[TBL] [Abstract][Full Text] [Related]
17. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL; Miklos DB; Jacobson CA; Perales MA; Kersten MJ; Oluwole OO; Ghobadi A; Rapoport AP; McGuirk J; Pagel JM; Muñoz J; Farooq U; van Meerten T; Reagan PM; Sureda A; Flinn IW; Vandenberghe P; Song KW; Dickinson M; Minnema MC; Riedell PA; Leslie LA; Chaganti S; Yang Y; Filosto S; Shah J; Schupp M; To C; Cheng P; Gordon LI; Westin JR;
N Engl J Med; 2022 Feb; 386(7):640-654. PubMed ID: 34891224
[TBL] [Abstract][Full Text] [Related]
18. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topp MS; van Meerten T; Houot R; Minnema MC; Bouabdallah K; Lugtenburg PJ; Thieblemont C; Wermke M; Song KW; Avivi I; Kuruvilla J; Dührsen U; Zheng Y; Vardhanabhuti S; Dong J; Bot A; Rossi JM; Plaks V; Sherman M; Kim JJ; Kerber A; Kersten MJ
Br J Haematol; 2021 Nov; 195(3):388-398. PubMed ID: 34590303
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma.
Kato K; Makita S; Goto H; Kanda J; Fujii N; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
Int J Clin Oncol; 2022 Jan; 27(1):213-223. PubMed ID: 34599413
[TBL] [Abstract][Full Text] [Related]
20. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
